Jane Street Group LLC Makes New Investment in Precision BioSciences, Inc. (NASDAQ:DTIL)

Jane Street Group LLC bought a new position in Precision BioSciences, Inc. (NASDAQ:DTIL) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 38,364 shares of the company’s stock, valued at approximately $146,000. Jane Street Group LLC owned 0.50% of Precision BioSciences as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of DTIL. Lynx1 Capital Management LP acquired a new stake in Precision BioSciences in the fourth quarter worth $2,919,000. Moloney Securities Asset Management LLC raised its holdings in Precision BioSciences by 177.0% in the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock worth $335,000 after purchasing an additional 56,100 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Precision BioSciences in the fourth quarter worth $211,000. Renaissance Technologies LLC raised its holdings in Precision BioSciences by 36.2% in the fourth quarter. Renaissance Technologies LLC now owns 109,798 shares of the company’s stock worth $418,000 after purchasing an additional 29,200 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Precision BioSciences in the fourth quarter worth $67,000. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Precision BioSciences Trading Up 7.0%

Shares of NASDAQ:DTIL opened at $5.49 on Friday. Precision BioSciences, Inc. has a 12 month low of $3.61 and a 12 month high of $12.54. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The company’s fifty day simple moving average is $4.98 and its 200 day simple moving average is $5.16. The firm has a market cap of $60.87 million, a price-to-earnings ratio of 91.52 and a beta of 1.55.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($2.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($1.78). Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $5.00 million. As a group, research analysts forecast that Precision BioSciences, Inc. will post -1.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a report on Wednesday, May 21st.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.